Pfizer Tests BCMA Bispecific Antibody Elranatamab in Relapsed Multiple Myeloma

Multiple myeloma remains one of the more challenging blood cancers to treat, particularly for patients who have relapsed or become refractory to standard therapies including proteasome inhibitors and immunomodulatory drugs. New mechanisms of action are critically needed for this population, which often has limited therapeutic options and poor prognosis.

This Phase 1 trial evaluated PF-06863135, now known as elranatamab, a BCMA-CD3 bispecific antibody engineered to engage T cells and redirect them to destroy BCMA-expressing myeloma cells. The study was designed as a dose-escalation trial to establish safety, tolerability, and the maximum tolerated dose in patients with relapsed or refractory multiple myeloma. Arms included monotherapy delivered intravenously or subcutaneously, and combination cohorts pairing elranatamab with dexamethasone or lenalidomide.

As a Phase 1 study, the primary endpoints centered on safety and dose determination rather than efficacy. The trial is now completed, and the foundational dosing data generated here informed subsequent Phase 2 development. Elranatamab ultimately received FDA Accelerated Approval in August 2023 under the brand name Elrexfio for adults with relapsed or refractory multiple myeloma who had received at least four prior lines of therapy.

For clinicians, this trial represents the origin point of a now-approved therapy. Understanding its Phase 1 roots helps contextualize the mechanism, dosing rationale, and safety profile seen in practice. Subcutaneous administration, explored here, became the approved delivery route — relevant for outpatient tolerability.

Caveats include the small sample sizes typical of Phase 1 work and the absence of efficacy as a primary endpoint. The full dataset beyond the abstract is not publicly available, limiting detailed analysis. Nonetheless, the completed status and subsequent regulatory approval validate the trial's scientific foundation.